Almenat SAS

5 records, newest first. Each line links to the FDA page it came from.

Refusal charges, in plain English

• UNAPPROVED2 refused lines

  Unapproved new drug

  The product appeared to be a new drug within the meaning of section 201(p) of the FD&C Act without an approved New Drug Application. FDA can apply this charge to a food or supplement whose labeling presents it for drug uses.

• COLOR LBLG1 refused line

  Artificial coloring not declared

  The product appeared to contain an artificial coloring without labeling that states that fact.

• DIETARYLBL1 refused line

  Not identified as a dietary supplement

  The label appeared not to identify the product with the term "dietary supplement" (which may be modified with the name of an ingredient).

• NO ENGLISH1 refused line

  Required label information not in English

  Information that must appear on the label appeared not to be given in English, or not to be repeated in every language used on the label.

Questions about Almenat SAS

Is Almenat SAS on an FDA import alert?

Yes. As of October 26, 2026, Almenat SAS is on the red list of FDA Import Alert 54-16, “Foods/supplements with active pharmaceutical ingredient”, for biq-fel; FDA published the listing on July 9, 2026.

Has FDA refused shipments from Almenat SAS?

Yes. FDA refused 4 shipment lines from Almenat SAS between January 7, 2026 and September 17, 2026. The most recent, on September 17, 2026, was vitamin, n.e.c., charged as COLOR LBLG (artificial coloring not declared).

Why did FDA refuse Almenat SAS's shipments?

The most frequent charges are UNAPPROVED (unapproved new drug, 2 lines) and COLOR LBLG (artificial coloring not declared, 1 line).

What is Almenat SAS's FEI number?

Almenat SAS's FDA Establishment Identifier (FEI) is 3039947198.

Can shipments from Almenat SAS still enter the U.S.?

Shipments of biq-fel from Almenat SAS can be detained without physical examination under Import Alert 54-16; FDA releases them only if evidence shows they do not have the listed violation. Importers must consider this listing in their FSVP evaluation (21 CFR 1.505).